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Acinetobacter baumannii is opportunistic Gram-negative bacterial 
pathogen which causes hospital-acquired infections. Existence of 
numerous antibiotic-resistant strains of A. baumanii emphasizing the 
need for the development of new antimicrobials to combat them. 
Alanineracemase (Alr) is a pyridoxal 5'-phosphate dependent enzyme 
present in A. baumanii is responsible for racemization between 
enantiomers of alanine. As D-alanine is an essential component of the 
bacterial cell wall, its inhibition is lethal to prokaryotes, making it an 
excellent antibiotic drug target. The structure of AlrAba provides the 
template required for future structure-based drug-design. In this study, 
insilico docking studies of the sideromycins albomycin and salmycin 
against alanineracemase was performed. The binding energy and 
docked poses evaluation enabled us to conclude that the sideromycins 
could serve as potential inhibitor of alanine racemase which would be 
useful in the fight against A. baumanii. 
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1. INTRODUCTION  
 The first report of Acinetobacter infections in a hospital setting, within an intensive care unit (ICU), 
dates back to the 1960s. Acinetobacter baumanii is a versatile biological agent causing severe infections to 
patients hospitalized for other ailments. A. baumannii is the fifth most common cause of infections affecting 
patients admitted to ICUs worldwide, reaching 9% of all infections in this group (Rivera et al., 2016). Morbidity 
and mortality associated with these infections is high, with crude mortality rates ranging from 20 - 60%. The 
intrinsic antimicrobial resistance of A. baumannii, as well as its association with hospital and antimicrobial 
exposure and immunosuppressive states, make selection of appropriate antimicrobial therapy simultaneously 
more difficult and more important (Kassamali et al., 2015). 
 Alanine racemase (EC 5.1.1.1) is a pyridoxal 50-phosphate (PLP)- dependent enzyme which catalyses 
racemization between l-alanine and d-alanine (Walsh, 1989). D-Alanine is an essential building block of 
peptidoglycan, a critical component of the bacterial cell wall (Hols et al., 1997). Alanine racemase (Alr) is the 
sole source of D-alaninein many bacteria and its inhibition is lethal, making the enzyme an attractive antibiotic 
drug target (Lambert and Neuhaus, 1972).  
 Sideromycins are antibiotics covalently linked to siderophoresin which the siderophore moiety 
performs targeting and delivery functions and their by affords enhance cellular uptake of the antibiotic for 
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strains expressing the appropriate transport machinery. Their minimal inhibitory concentration is at least 100-
fold lower than that of antibiotics that enter cells by diffusion. This is particularly relevant for gram-negative 
bacteria because the outer membrane, which usually forms a permeability barrier, in this case actively 
contributes to the uptake of sideromycins. Albomycins and salmycins are classes of sideromycins discovered 
from Streptomycetes.  
 In silico modeling is the bypass for the traditional drug testing compounds, synthesized in time 
consuming multi step process against biological screens. It is the new approach to clinical chemistry for the 
optimization of screening and testing by means of the observation on particular compound. An increasing 
number of proteins crystallographic structures are becoming available based on high throughput structural 
genomics projects thus prediction of a potential lead and its potential target is a fundamental step in order to 
investigate the molecular recognition mechanisms of protein (Khamkar et al., 2013). The present study 
attempted to perform in silico docking of actinobacteria-derived sideromycins, albomycin and salmycin against 
the alanine racemase enzyme target of Acinetobacter baumanii. 
 
2. RESEARCH METHOD 
The accession of the target protein 
 The three dimensional structure of alanine racemase ACE (PDB :4QHR ) was downloaded from RCSB 
protein data bank (http://www.rcsb.org/pdb/home). The protein was prepared in the standard format with 
correction to bond orders.  
Ligand selection 
 The chemical structure of ligands such as albomycin and salmycinin SMILES formatwas obtained from 
PubChem. It was prepared and docked in the site of existing inhibitor to generate the atomic coordinates.  
Target and ligand optimization 
 For docking analysis, PDB coordinates of the target protein and ligand molecules were optimized by 
CDOCKERprogram to perform the ligand – protein docking (Discovery Studio 2.4 version).These coordinates 
had the minimum energy and stable conformation.  
Analysis of target active binding sites 
 The active sites are the coordinates of the ligand in the original target protein grid and these active 
binding sites of target protein were analyzed using the Drug Discovery Studio version 2.4 and 3D LigandSite 
virtual tools (Wass et al., 2010).At each step of the simulation, the energy interaction of the ligand and protein 
were evaluated using the atomic affinity potentials computed on a grid. The remaining parameters were set as 
default. 
3. RESULTS AND ANALYSIS  
 The results given in Figure 1 and Figure2 depict the docking snapshots of the ligands bound to the 
protein enzyme alanine racemase. Around 10 poses were generated and 4 poses conformation were found to be 
ideal. The binding energy of the top poses conformations were -39.51kcals /moland to -36.7 Kcals/mols. The 
rotatable bonds were greater than 8, maximum conformation and pose generated because of the increased 
number of rotatable bonds in the ligand.The ligand binding interactions were more hydrophilic with Glu 150 
with Hydroxyl group, Phe 152, Leu 108 and Ileu 109 with the Hydrogen bonding and Ilue 116 with the 
Carboxyl group. 
 
                                                              
Figure 1. Docking results of albomycin with alanineracemase and the ligand binding interactions 
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Figure 2. Docking results of salmycin with alanineracemase and the ligand binding interactions 
4. CONCLUSION  
 The results of the study have provided scope for a novel concept of handling nosocomial infections. A 
new approach to inhibition shows great promise for structure-based drug development is targeting enzymes like 
alanine racemase, hence typically, dysfunction of alanine racemase results in death of bacteria. This has spurred 
a vast interest to identify pharmacologically active small-molecule inhibitors of alanine racemase. Further 
invitro / exvivo studies may be warranted to further validate the claim and prove it as an ideal drug target. . The 
binding energy and docked poses evaluation enables us to conclude that both the actinobacterial sideromycins, 
albomycin and salmycin could serve as potential antibiotics against A. baumanii 
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